A Combinatorial Biomarker for Infection Diagnosis in Children
Launched by UNIVERSITÄT DES SAARLANDES · Aug 1, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method to help doctors diagnose infections in children, particularly those with respiratory tract infections and fever. The researchers are looking at a special combination of biomarkers called BV, which includes three specific indicators (TRAIL, IP-10, and CRP). By comparing children who have this BV test with those who do not, the study aims to see how well BV can help determine whether an infection is bacterial or viral. This could lead to better treatment decisions and outcomes for young patients.
To participate in the trial, children must be suspected of having an acute bacterial or viral infection and need to take at least one BV test during their visit to the hospital. The study is currently recruiting participants of all genders aged 15 and older. Families considering this trial should know that it involves monitoring treatment plans, hospital stays, and overall health outcomes based on the BV test results. This research could significantly improve how infections in children are diagnosed and treated in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Suspicion of acute bacterial or viral infection
- • Requirement of at least one BV test during medical presentation
- Exclusion Criteria:
- • lack of informed consent
About Universität Des Saarlandes
The Universität des Saarlandes is a distinguished academic institution located in Germany, recognized for its commitment to advancing research and education in the medical and health sciences. As a clinical trial sponsor, the university leverages its robust interdisciplinary expertise and state-of-the-art facilities to facilitate innovative research initiatives aimed at addressing critical health challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring rigorous adherence to ethical standards and regulatory compliance throughout the clinical trial process. Through its dedication to scientific excellence and patient-centered research, Universität des Saarlandes plays a vital role in contributing to the development of novel therapeutic interventions and improving healthcare outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bonn, , Germany
Würzburg, , Germany
Homburg, , Germany
Berlin, , Germany
Patients applied
Trial Officials
Cihan Papan, MD
Principal Investigator
Universität des Saarlandes
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported